[An antitumor osteotropic agent based on tumor necrosis factor]

Area of Science:

• Biomaterials Science
• Drug Delivery
• Oncology

Background:

• Bone metastases represent a significant challenge in cancer treatment.
• Current therapies often lack targeted delivery to bone tissue.
• Tumor necrosis factor-alpha (TNF-alpha) and double-stranded ribonucleic acid (dsRNA) exhibit antitumor properties.

Purpose of the Study:

• To design and synthesize a novel drug conjugate for targeted bone metastases treatment.
• To combine antitumor agents with a bone-targeting moiety.
• To characterize the physicochemical properties and bone-affinity of the designed drug.

Main Methods:

• Synthesis of dextran conjugates with TNF-alpha and alendronic acid.
• Self-assembly of molecular structures and separation via gel filtration (Sepharose CL-6B).
• Characterization using electrophoresis, transmission electron microscopy, and sorption/desorption assays.

Main Results:

• Successful synthesis of TNF-alpha and alendronic acid conjugates with dextran.
• Formation of self-assembled drug structures with particle sizes of 30-40 nm.
• Demonstrated enhanced affinity of TNF-alpha conjugates to hydroxyapatite compared to native TNF-alpha.

Conclusions:

• A novel drug conjugate effectively targets bone tissue through bisphosphonate's affinity for hydroxyapatite.
• The designed molecular structure integrates antitumor activity with targeted delivery for bone metastases.
• This approach holds promise for improved therapeutic strategies against bone metastases.